Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.600
+0.010 (0.28%)
At close: Jun 3, 2026, 4:00 PM EDT
3.551
-0.049 (-1.35%)
After-hours: Jun 3, 2026, 6:17 PM EDT
Voyager Therapeutics Revenue
Voyager Therapeutics had revenue of $2.59M in the quarter ending March 31, 2026, a decrease of -59.94%. This brings the company's revenue in the last twelve months to $36.49M, down -45.50% year-over-year. In the year 2025, Voyager Therapeutics had annual revenue of $40.37M, down -49.53%.
Revenue (ttm)
$36.49M
Revenue Growth
-45.50%
P/S Ratio
5.96
Revenue / Employee
$258,823
Employees
141
Market Cap
217.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.37M | -39.63M | -49.53% |
| Dec 31, 2024 | 80.00M | -170.01M | -68.00% |
| Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
| Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
| Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
| Dec 31, 2020 | 171.13M | 66.74M | 63.93% |
| Dec 31, 2019 | 104.39M | 96.77M | 1,270.14% |
| Dec 31, 2018 | 7.62M | -2.52M | -24.82% |
| Dec 31, 2017 | 10.14M | -4.09M | -28.73% |
| Dec 31, 2016 | 14.22M | -3.11M | -17.96% |
| Dec 31, 2015 | 17.33M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fulcrum Therapeutics | 80.00M |
| Arcturus Therapeutics Holdings | 54.71M |
| Coherus Oncology | 46.88M |
| Atrium Therapeutics | 36.68M |
| Foghorn Therapeutics | 28.22M |
| LENZ Therapeutics | 20.99M |
| Whitehawk Therapeutics | 7.15M |
| Camp4 Therapeutics | 3.93M |
VYGR News
- 2 days ago - Voyager Therapeutics announces FDA clearance for VY1706 IND application - TheFly
- 2 days ago - Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease - GlobeNewsWire
- 21 days ago - Voyager Therapeutics presents GLP for toxicology data for VY1706 - TheFly
- 21 days ago - Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 - GlobeNewsWire
- 27 days ago - Voyager Therapeutics reports Q1 EPS (47c), consensus (53c) - TheFly
- 27 days ago - Voyager Reports First Quarter 2026 Financial and Operating Results - GlobeNewsWire
- 27 days ago - Voyager Therapeutics Quarterly report: Q1 2026 - Filings
- 27 days ago - Voyager Therapeutics Earnings release: Q1 2026 - Filings